What is Irfen Quiktabs?
Irfen Quiktabs is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain, and helps to relieve symptoms of arthritis (osteoarthritis, rheumatoid arthritis, or juvenile arthritis), such as inflammation, swelling, stiffness, and joint pain. Irfen Quiktabs does not cure arthritis and will help you only as long as you continue to take it.
In addition, Irfen Quiktabs can be used to treat fever, menstrual cramps, and other conditions as determined by your doctor.
Irfen Quiktabs is available both over-the-counter (OTC) and with your doctor's prescription.
Irfen Quiktabs indications
Carefully consider the potential benefits and risks of Irfen Quiktabs
Oral Suspension and other treatment options before deciding to use Irfen Quiktabs. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
In Pediatric Patients, Irfen Quiktabs
Oral Suspension is indicated:
- For reduction of fever in patients aged 6 months up to 2 years of age.
- For relief of mild to moderate pain in patients aged 6 months up to 2 years of age.
- For relief of signs and symptoms of juvenile arthritis.
In Adults, Irfen Quiktabs
Oral Suspension is indicated:
- For treatment of primary dysmenorrhea.
- For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of Irfen Quiktabs in conjunction with aspirin, the combination cannot be recommended.
How should I use Irfen Quiktabs?
Use Irfen Quiktabs capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Irfen Quiktabs capsules comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Irfen Quiktabs capsules refilled.
- Take Irfen Quiktabs capsules by mouth with or without food. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.
- Swallow Irfen Quiktabs capsules whole. Do not break, crush, or chew before swallowing.
- Take Irfen Quiktabs capsules with a full glass of water (8 oz/240 mL) as directed by your doctor.
- If you miss a dose of Irfen Quiktabs capsules and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about the proper use of Irfen Quiktabs capsules.
Uses of Irfen Quiktabs in details
Use: Labeled Indications
Oral: Inflammatory diseases and rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, osteoarthritis
Irfen Quiktabs injection (Caldolor): Management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics in adults and children 6 months and older; reduction of fever in adults and children 6 months and older.
Irfen Quiktabs lysine injection (NeoProfen): Patent ductus arteriosus (PDA): To close a clinically significant PDA in premature infants weighing between 500-1500 g who are no more than 32 weeks of gestational age when usual medical management (eg, diuretics, fluid restriction, respiratory support) is ineffective.
OTC labeling: Reduction of fever; management of pain due to headache, migraine, sore throat, arthritis, physical or athletic overexertion (eg, sprains/strains), menstrual pain, dental pain, minor muscle/bone/joint pain, backache, pain due to the common cold and flu
Off Label Uses
Gout, acute flares
Clinical experience suggests the utility of Irfen Quiktabs as an alternative option for acute gout flares.
Based on the 2012 American College of Rheumatology guidelines for management of gout, NSAIDs are effective and recommended agents in the treatment of acute gout flares.
Pericarditis
Data from double-blind, placebo-controlled, multicenter trials indicate that colchicine in combination with aspirin or Irfen Quiktabs significantly reduces the incidence of symptoms at 72 hours and the risk of recurrence in acute and recurrent pericarditis. Based on Brazilian Society of Cardiology guidelines for the management of myocarditis and pericarditis and European Society of Cardiology (ESC) guidelines for the management of pericardial diseases, nonsteroidal anti-inflammatory drugs (NSAIDs) (typically, aspirin or Irfen Quiktabs) in combination with colchicine are recommended as first-line treatment to manage pain and resolve inflammation in idiopathic and viral acute and recurrent pericarditis.
Irfen Quiktabs description
Irfen Quiktabs is a member of the propionic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is a racemic mixture of [+]S- and [-]R-enantiomers.
The chemical name for Irfen Quiktabs is (±)-2-(4-isobutylphenyl) propionic acid. It has a molecular weight of 206.28 and a molecular formula of C13H18O2.
Irfen Quiktabs is a colorless, crystalline stable solid, with a melting point of 75-77°C. It is relatively insoluble in water but readily soluble in most organic solvents. Irfen Quiktabs has a pKa of 4.43±0.03 and an n-octanol/water partition coefficient of 11.7 at pH 7.4.
Irfen Quiktabs has shown analgesic, anti-inflammatory and antipyretic activity in both animal and human studies. These properties provide symptomatic relief of inflammation and pain.
Irfen Quiktabs dosage
2.1 Recommended Dose
A course of therapy is three doses of Irfen Quiktabs Lysine administered intravenously (administration via an umbilical arterial line has not been evaluated). An initial dose of 10 mg per kilogram is followed by two doses of 5 mg per kilogram each, after 24 and 48 hours. All doses should be based on birth weight. If anuria or marked oliguria (urinary output <0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose of Irfen Quiktabs Lysine, no additional dosage should be given until laboratory studies indicate that renal function has returned to normal. If the ductus arteriosus closes or is significantly reduced in size after completion of the first course of Irfen Quiktabs Lysine, no further doses are necessary. If during continued medical management the ductus arteriosus fails to close or reopens, then a second course of Irfen Quiktabs Lysine, alternative pharmacological therapy, or surgery may be necessary.
2.2 Directions for Use
For intravenous administration only.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Do not use Irfen Quiktabs Lysine if particulate matter is observed.
After the first withdrawal from the vial, any solution remaining must be discarded because Irfen Quiktabs Lysine contains no preservative.
For administration, Irfen Quiktabs Lysine should be diluted to an appropriate volume with dextrose or saline. Irfen Quiktabs Lysine should be prepared for infusion and administered within 30 minutes of preparation and infused continuously over a period of 15 minutes. The drug should be administered via the IV port that is nearest the insertion site. After the first withdrawal from the vial, any solution remaining must be discarded because Irfen Quiktabs Lysine contains no preservative.
Since Irfen Quiktabs Lysine is potentially irritating to tissues, it should be administered carefully to avoid extravasation.
Irfen Quiktabs Lysine should not be simultaneously administered in the same intravenous line with Total
Parenteral Nutrition (TPN). If necessary, TPN should be interrupted for a 15-minute period prior to and after drug administration. Line patency should be maintained by using dextrose or saline.
Irfen Quiktabs interactions
See also:
What other drugs will affect Irfen Quiktabs?
Coumarin-Type Anticoagulants: Several short-term controlled studies failed to wshow that Irfen Quiktabs significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on coumarin-type anticoagulants. However, because bleeding has been reported when Irfen Quiktabs and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering Irfen Quiktabs to patients on anticoagulants.
Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including Irfen Quiktabs, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug. Single dose bioavailability studies in normal volunteers have failed to wshow an effect of aspirin on Irfen Quiktabs blood levels. Correlative clinical studies have not been performed.
Methotrexate: Apo-Irfen Quiktabs, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices. This may indicate that Irfen Quiktabs could enhance the toxicity of methotrexate. Caution should be used if Irfen Quiktabs is administered concomitantly with methotrexate.
H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with Irfen Quiktabs had no substantive effect on Irfen Quiktabs serum concentrations.
Furosemide: Clinical studies, as well as random observations, have shown that Irfen Quiktabs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with Irfen Quiktabs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.
Lithium: Apo-Irfen Quiktabs produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers. The mean minimum lithium concentration increased 15% and the renal clearance of lithium was decreased by 19% during this period of concomitant drug administration.
This effect has been attributed to inhibition of renal prostaglandin synthesis by Irfen Quiktabs. Thus, when Irfen Quiktabs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. (Read circulars for lithium preparation before use of such concurrent therapy).
Irfen Quiktabs side effects
See also:
What are the possible side effects of Irfen Quiktabs?
6.1 Clinical Trials Experience
The most frequently reported adverse events with Irfen Quiktabs Lysine were as shown in Table 1.
6.2 Renal Function
Compared to placebo, there was a small decrease in urinary output in the Irfen Quiktabs group on days 2-6 of life, with a compensatory increase in urine output on day 9. In other studies, adverse events classified as renal insufficiency including oliguria, elevated BUN, elevated creatinine, or renal failure were reported in Irfen Quiktabs treated infants.
6.3 Additional Adverse Events
The adverse events reported in the multicenter study and of unknown association include tachycardia, cardiac failure, abdominal distension, gastroesophageal reflux, gastritis, ileus, inguinal hernia, injection site reactions, cholestasis, various infections, feeding problems, convulsions, jaundice, hypotension, and various laboratory abnormalities including neutropenia, thrombocytopenia, and hyperglycemia.
6.4 Post-marketing Experience
The following adverse reactions have been identified from spontaneous post-marketing reports or published literature: gastrointestinal perforation, necrotizing enterocolitis, and pulmonary hypertension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency, or establish a causal relationship to drug exposure.
Irfen Quiktabs contraindications
See also:
What is the most important information I should know about Irfen Quiktabs?
This medicine may cause life-threatening heart or circulation problems such as heart attack or stroke, especially if you use it long term. Do not use Irfen Quiktabs just before or after heart bypass surgery (coronary artery bypass graft, or CABG).
Get emergency medical help if you have chest pain, weakness, shortness of breath, slurred speech, or problems with vision or balance.
This medicine may also cause serious effects on the stomach or intestines, including bleeding or perforation (forming of a hole). These conditions can be fatal and can occur without warning while you are taking Irfen Quiktabs, especially in older adults.
Call your doctor at once if you have symptoms of stomach bleeding such as black, bloody, or tarry stools, or coughing up blood or vomit that looks like coffee grounds.
Do not take more of this medication than is recommended. An overdose of Irfen Quiktabs can cause damage to your stomach or intestines. Use only the smallest amount of Irfen Quiktabs needed to get relief from your pain, swelling, or fever.
Active ingredient matches for Irfen Quiktabs:
Ibuprofen in Latvia.
List of Irfen Quiktabs substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Irfen-800 SR (Lithuania) | |
| Irufen (Bangladesh) | |
| Isdibudol (Spain) | |
| Isdol (Spain) | |
| Isisfen (United Kingdom) | |
| Isofen P | |
| Isofen P 400+325 Tablet (Prayas Pharmaceuticals) | $ 0.01 |
| Iton (Taiwan) | |
| Iton 200 mg x 1000's | |
| Itonfen (Taiwan) | |
| Itonfen 200 mg x 1000's | |
| Jaefen (Pakistan) | |
| Jamp Ibuprofen (Canada) | |
| Jazofen (Kuwait) | |
| Jazofen 200 | |
| Jenaprofen (Germany) | |
| Tablet, Film-Coated; Oral; Ibuprofen 400 mg (Jenapharm) | |
| Tablet, Film-Coated; Oral; Ibuprofen 600 mg (Jenapharm) | |
| Tablets, Film-Coated; Oral; Ibuprofen 400 mg (Jenapharm) | |
| Tablets, Film-Coated; Oral; Ibuprofen 600 mg (Jenapharm) | |
| Jenaprofen 400 | |
| Jenaprofen 800 | |
| Jenaprofen Retard | |
| Capsule, Retard; Oral; Ibuprofen 400 mg | |
| Tablet, Retard; Oral; Ibuprofen 800 mg | |
| Capsules, Retard; Oral; Ibuprofen 400 mg | |
| Tablets, Retard; Oral; Ibuprofen 800 mg | |
| Jie Le (China) | |
| Jihao (China) | |
| Jiubaofen (China) | |
| Jointral (Italy) | |
| Jr. Strength Motrin (United States) | |
| Jumbo Ibuprofen (Netherlands) | |
| Junidol (Peru) | |
| Junifen (Belgium, Luxembourg, Spain) | |
| Junimol (Thailand) | |
| Junimol 100 mg/5 mL x 60 mL | |
| Junimol 120mg/5ml Suspension (Elder Pharmaceuticals Ltd) | $ 0.29 |
| Junimol 170mg Tablet (Elder Pharmaceuticals Ltd) | $ 0.08 |
| Junimol 250mg Tablet (Elder Pharmaceuticals Ltd) | $ 0.11 |
| Junimol 80mg Tablet (Elder Pharmaceuticals Ltd) | $ 0.06 |
| Junior Ibuprofen (Malta) | |
| Junior Strenght Advil (United States) | |
| Junior Strenght Motrin (United States) | |
| Junior Strength Advil (Canada) | |
| Tablet, Chewable; Oral; Ibuprofen 100 mg | |
| Tablet; Oral; Ibuprofen 100 mg | |
| Tablets, Chewable; Oral; Ibuprofen 100 mg | |
| Tablets; Oral; Ibuprofen 100 mg | |
See 4785 substitutes for Irfen Quiktabs | |
References
- DailyMed. "IBUPROFEN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "ibuprofen". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "ibuprofen". http://www.drugbank.ca/drugs/DB01050 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Irfen Quiktabs are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Irfen Quiktabs. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
